Zurich / Singapore / Boston, March 2017 – Venture Valuation is looking back to a new record year in terms of valuations.
The past year has seen a new record number of valuations provided by Venture Valuation to its clients with 45 valuations in 2016 compared to 31 in 2015. Over the two year period, the Venture Valuation team have provided their valuation services in geographies spanning Asia, Europe, the USA and Canada, including in Hong Kong, China, India, Singapore, UK, Germany, Italy, Finland, Switzerland, Spain, France, Austria, Sweden, Belgium, and the Netherlands. Asia represented around 15%, Europe 70% and the USA 15% of all valuations.
Venture Valuation offers company and individual product and asset valuations. Over the period, around 40% were whole company valuations and 60% valuations of individual products. Most of the valuations were used for fund-raising, M&A, and licensing deals, as well as for compliance reasons including fairness opinions for reverse mergers and other transactions.
Of the therapeutic companies and product valuations, about 25% had the lead product/ were still in pre-clinical development, about 20% in phase II and around 33% had/ were products already on the market. The average value of a company was around USD 50m and the average product valuation was around USD 150m driven mostly by products already on the market.
Clients of Venture Valuation were investors (58%) such as Pharma, corporate investors, venture capital investors, family offices, business angels and universities, and the companies themselves (42%).
The life sciences sectors represented included therapeutic biotechnology, diagnostics, medtech, and other biotech such as agro, veterinarian, nutraceuticals, TCM, R&D services, healthtech and industrial biotech. Within the therapeutics sector, the diverse range of companies and products were focused on cancer, CNS, dermatology, haematology, gene therapy, anti-infectives, arthritis, pain and many others.
The average company valuation took around 4 to 6 weeks to complete and the average product valuation around 2-3 weeks. With a staff of over 25 people combining business and sciences backgrounds in North America, Europe and Asia and with the in-house database Biotechgate, Venture Valuation is a global leader in valuation of biotech, medtech, diagnostics, and pharma companies.
Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 44,000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals, associated financial information on individual deals and a unique life sciences investors database.
Venture Valuation AG (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland/Ireland/UK (Europe), USA/Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.
For further information, please contact: Patrik Frei, CEO Venture Valuation, firstname.lastname@example.org